DNA Script has raised $38.5 million in new financing to commercialize a process that it claims is the first big leap forward in manufacturing genetic material.

The revolution in synthetic biology that’s reshaping industries from medicine to agriculture rests on three, equally important pillars.

They include: analytics — the ability to map the genome and understand the function of different genes; synthesis — the ability to manufacture DNA to achieve certain functions; and gene editing — the CRISPR-based technologies that allow for the addition or subtraction of genetic code.

New technologies have already been introduced to transform the analytics and editing of genomes, but little progress has been made over the past 50 years in the ways in which genetic material is manufactured. That’s exactly the problem that DNA Script is trying to solve.

Traditionally, making DNA involved the use of chemical compounds to synthesize (or write) DNA in chains that were limited to around 200 nucleotide bases. Those synthetic pieces of genetic code are then assembled to make a gene.

DNA Script’s technology holds the promise of making longer chains of nucleotides by mirroring the enzymatic process through which DNA is assembled within cells — with fewer errors and no chemical waste material. The enzymatic process can accelerate commercial applications in healthcare, chemical manufacturing and agriculture.

“Any technology that can make that faster is going to be very valuable,” says Christopher Voigt, a synthetic biologist at the Massachusetts Institute of Technology in Cambridge, told the journal Nature.

DNA Script isn’t the only company in the market that’s looking to make the leap forward in enzymatic DNA production. Nuclear, a startup working with Harvard University’s famed geneticist, George Church, and Ansa Bio, a startup affiliated with Jay Keasling’s Berkeley lab at the University of California, are also moving forward with the technology.

But the Paris-based company has achieved some milestones that would make its technology potentially the first to come to market with a commercially viable approach.

Image Credit:  Envato

Read more at techcrunch.com

News This Week

NanoApps Athletics Inc. Established

Frank Boehm (NanoApps Medical Inc. founder) and Amanda Scott (NA CEO) join NanoApps Athletics Inc. NanoApps Athletics Inc proposes a unique synergistic biochemical/nanomedical strategy for the expedited repair and healing of Achilles tendon micro [...]

Light in a new light

In a paper published in Nature's NPJ Quantum Information ("Multiphoton quantum-state engineering using conditional measurements"), Omar Magaña-Loaiza, assistant professor in the Louisiana State University (LSU) Department of Physics & Astronomy, and his team of [...]

Brain-computer interfaces without the mess

It sounds like science fiction: controlling electronic devices with brain waves. But researchers have developed a new type of electroencephalogram (EEG) electrode that can do just that, without the sticky gel required for conventional [...]